According to the development plan, CMS is building a new product production base at the new region of Pingshan, which is located in the Shenzhen National Pharmaceutical Industry Park, covering an area of 36,422.4 square meters, with nice environment and convenient traffic.
The production base is mainly used to produce Tyroserleutide (CMS024), which is a National Class One New Drug researched and developed by CMS and with independent intellectual property rights. The construction project is made up of API workshop, preparation workshop, medical device workshop, power house, office building, quality control and test center, logistics center (warehouse) and sewage treatment facilities.
The construction work of the principal part of the project was started on December 22, 2012, and was successfully completed on May 11, 2013.